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OBJECTIVES The goal of this study was to evaluate the cellular and extracellular composition of human
coronary arterial in-stent restenosis after various periods of time following stent deployment.
BACKGROUND Neointimal in-growth rather than stent recoil is thought to be important for coronary arterial
in-stent restenosis. There is only limited data on the cellular and extracellular composition
changes with time after stent deployment.
METHODS We analyzed 29 coronary arterial in-stent restenotic tissue samples (14 left anterior
descending coronary artery, 10 right coronary artery, and 5 left circumflex artery) retrieved by
using directional coronary atherectomy from 25 patients at 0.5 to 23 (mean, 5.7) months after
deployment of Palmaz-Schatz stents employing histochemical and immunocytochemical
techniques.
RESULTS Cell proliferation was low (0% to 4%). Myxoid tissue containing extracellular matrix (ECM)
enriched with proteoglycans was found in 69% of cases and decreased over time after stenting.
Cell-depleted areas were found in 57% of cases and increased with time after stenting.
Versican, biglycan, perlecan, and hyaluronan were present with varying individual distribu-
tions in all samples. Positive transforming growth factor-1 staining was found in 80% of
cases. Immunostaining with alpha-smooth muscle actin identified the majority of cells as
smooth muscle cells with occasional macrophages present (12 cells per section).
CONCLUSIONS These data suggest that enhanced ECM accumulation rather than cell proliferation
contribute to later stages of in-stent restenosis. Balloon angioplasty of in-stent restenosis may,
therefore, fail due to ECM changes during: 1) additional stent expansion, 2) tissue extrusion
out of the stent, or 3) tissue compression. (J Am Coll Cardiol 2002;40:2072–81) © 2002
by the American College of Cardiology Foundation
Although intracoronary stent implantation has been shown
to reduce the rate of restenosis and to improve clinical
outcome compared with standard balloon angioplasty (1),
in-stent restenosis rate is still 15% to 30% in six months
(1–3). The mechanism of stent stenosis is not well under-
stood. Neointimal in-growth, rather than tissue remodeling
or stent recoil, is thought to be an important mechanism for
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in-stent restenosis because stents subject the artery to
permanent dilation. These ideas are supported by clinical
intravascular ultrasound studies (2,3) and animal studies (4).
Only a few histopathologic studies of stent restenosis
have been performed in patients with coronary or peripheral
artery disease (5–7). Myxoid tissue characterized by stellate-
shaped smooth muscle cells (SMC) in a loose extracellular
matrix (ECM) is a frequent observation in restenotic tissue
(5,6). Similar tissue has been found in coronary restenotic
lesions and, to a lesser extent, in primary atherosclerotic
lesions (8). Cell replication rates as measured by proliferat-
ing cell nuclear antigen (PCNA) vary according to the
study. For example, no PCNA-positive cells were found in
10 coronary stented restenotic samples (5), whereas approx-
imately 25% of the SMC of peripheral arterial stented
restenotic samples were PCNA-positive (6). Data on hu-
man coronary restenotic lesions after balloon angioplasty
show cell replication rates varying from mostly 1% (9) to
as much as 15.2% (10). The reasons for these differences are
not clear.
In the present study, we analyzed histopathologic sections
of human coronary arterial stent neointima retrieved by
directional atherectomy from 25 patients who underwent
previous Palmaz-Schatz stent deployment with the specific
aim of assessing cellularity, cell replication rate, and ECM
composition over time after stenting.
METHOD
Atherectomy specimens. Twenty-nine Palmaz-Schatz
coronary stent restenotic independent specimens (14 left
anterior descending coronary artery, 10 right coronary
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artery, and 5 left circumflex) were obtained from different
anatomical locations from 25 patients (male/female: 18/7;
age: 59  13 years) and analyzed separately. In four
patients, two different specimens were retrieved at different
sites within the stent. Specimens were retrieved percutane-
ously by directional coronary atherectomy using a Simpson
Coronary Atherocath (Devices for Vascular Intervention,
Redwood City, California) in the Massachusetts General
Hospital (Boston, Massachusetts) and Mitsui Memorial
Hospital (Tokyo, Japan) between August 1995 and Novem-
ber 1996. Indications for atherectomy were angiographically
documented stent restenosis with one of the following: 1)
positive exercise tolerance test with or without stable angina
(n  5: numbers 2, 6, 16, 20, 21 in Table 1), 2) recurrent
unstable angina pectoris (n  21), and 3) acute myocardial
infarction (n  3: numbers 1, 4, 12 in Table 1). Time
interval between initial stent deployment and later atherec-
tomy was 5.7 5.4 (range: 0.5 to 23) months (Table 1, Fig.
1). During the time intervals studied, all patients that had
in-stent restenosis where the stent was approachable were
used in the study. Tissue was taken from within the stent.
Great care was taken not to go outside the stent margins.
All stents were postdilated with a high-pressure balloon
from 14 to 18 atms. All patients had 75% stenosis for the
initial stent placements. Reference diameter of the vessel
was 3.0 mm. Fifteen tissue specimens were immediately
immersed in methyl Carnoy’s fixative for two to three days.
Fourteen specimens were immersed in 4% paraformalde-
hyde and divided for immunocytochemical staining and
transmission electron microscopy.
Histology. Histochemistry was performed on serial sec-
tions from each specimen. Each tissue section ranged in area
between 0.3 to 3.0 mm. Hematoxylin and eosin staining was
done to determine the cellularity and general morphologic
patterns of the specimens. The distribution of myxoid tissue
was graded semiquantitively: 1 for small foci and 2 for
large microscopic areas. Modified Movat’s staining was
performed to identify different ECM topological patterns
Abbreviations and Acronyms
ECM  extracellular matrix
HABP  hyaluronan binding protein
PBS  phosphate buffered saline
PCNA  proliferating cell nuclear antigen
SMC  smooth muscle cell
TGF-1  transforming growth factor-1
Table 1. Histopathologic Characteristics of Atherectomized Coronary Arterial In-Stent Restenotic Tissue Specimens
No.
Stent Age
(Months) Vessel Myxoid
Cell-
Depleted
ECM
Grade TGF-1
No. of
Ki-67
No. of
M Fibrin
1 0.5 LCX – – NA /EC – 12 NA
2 1.9 LAD 2 – 2 NA – NA –
3 2 LAD 1 – NA NA NA NA NA
4 2 LCX 2 : c 1, 5 NA – NA –
5 2.4 RCA 2 – 2, 4 NA – 3 NA
6 2.4 LAD 1 – 1 2 NA NA 
7 2.4 RCA 2 – 3 2/m 5 NA –
8 2.5 RCA 1 – 2 2/m 5 1 –
9 2.6 LCX 2 – 1 2/m 7 NA –
10 3 LCX – : c 4 NA – – –
11 3 LCX – : c 4 – – 1 NA
12 3.5 RCA 1 : NA NA 1 – –
13 3.6 RCA 1 – 2 1 3 NA –
14 4 LAD 1 – 1 1 – NA –
15 4.1 LAD 1 : c/PG 2 1 5 NA –
16 4.3 LAD – : c 1, 4 2 – NA NA
17 4.5 LAD 1 : c/PG 4 NA – – –
18 5 LAD 1 – 4 2/m – – –
19 5 LAD 1 : c 4 1 – – –
20 5.8 LAD 1 : c 4 2 1 – –
21 5.8 RCA 2 : c/PG 2 2/m 6 NA –
22 6 RCA 1 : PG 2 NA – NA NA
23 6.1 LAD 1 : c 4 NA – – NA
24 6.9 LAD – – 5 – – – 
25 9 RCA 1 : c/PG 4 – – – NA
26 11 LAD – : c/PG 1, 5 2 NA NA 
27 11 LAD – : c/PG 1, 5 2 1 NA 
28 23 RCA – : c 4 – 12 10 
29 23 RCA – : c 4 2/EC – 11 
Stent Age  interval (months) between stenting and DCA; Myxoid  1 for small foci, 2 for large microscopic area of myxoid tissue; Cell-Depleted  ‘c’ for collagen/‘PG’
for proteoglycan as a dominant ECM component; ECM Grade  1: PG as a dominant component, 2: PG  collagen, 3: PG  collagen, 4: PG  collagen, 5: collagen as a
dominant component; TGF-1  1 for rate of positivity  5%, 2 for rate of positivity 5%  in a microscopic field (100), EC meaning expression of extracellular area,
and ‘m’ meaning expression in myxoid tissue; M  macrophage; NA  not available.
DCA directional coronary angioplasty; ECM extracellular units; LAD left anterior descending artery; RCA right coronary artery; TGF-1 transforming growth factor-1.
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(11). For example, ECM was graded semiquantitatively for
the relative distribution of proteoglycans and collagen by
analyzing modified Movat’s staining: proteoglycans as a
dominant component (grade 1), proteoglycans  collagen
(grade 2), proteoglycans approximately equal to collagen
(grade 3), proteoglycans  collagen (grade 4), and collagen
as a dominant component (grade 5). The distribution of
transforming growth factor (TGF)-1 labeling was semi-
quantitatively graded: 1 for positivity of 5% of cells;
grade 2 for positivity 5%  of cells per microscopic field.
The total number of Ki-67-positive cells per slide was
counted visually at 400 magnification by two pathologists
(M.R. and I.C.), and the percentage of positive Ki-67 cells
in each tissue fragment was calculated. A cell-depleted area
is defined as a microscopic field area in which fewer than
320 cells/mm2 are found.
Antibodies. To identify SMCs, tissue sections were
stained with mouse monoclonal anti-human -smooth
muscle actin antibody (IgG2a, DAKO, Carpinteria, Cali-
fornia). Macrophages were identified by staining the spec-
imens with mouse monoclonal CD68 antibody (IgG3,
DAKO). To identify proliferating cells, tissue sections were
stained with monoclonal MIB-1 antibody (IgG1, Immuno-
tech Inc., Westbrook, Maine), which detects Ki-67 nuclear
antigen. Biotinylated hyaluronan binding protein (HABP)
was kindly provided by Dr. Charles B. Underhill (George-
town University Medical Center, Washington, DC) and
used as a probe for hyaluronan (12). Three different ECM
proteoglycans were analyzed. Versican was detected by
rabbit polyclonal antibody (versican anti-poly E, IgG) raised
against a fusion protein encoding for amino acid residues
387 to 692 of versican, which was kindly provided by Dr.
Richard LeBaron (University of Texas, San Antonio, Tex-
as). Perlecan was detected by rabbit antisera EY9 to purified
murine perlecan produced by Engelbreth-Holm-Swarm
tumor, which was kindly provided by Dr. John R. Hassell
(Shriners Hospital, Tampa, Florida) (13). Biglycan was
detected by antisera LF51 to human biglycan synthetic
peptide that was kindly provided by Dr. Larry W. Fisher
(National Institute of Dental Research, Bethesda, Mary-
land). Rabbit polyclonal affinity purified anti-human
TGF-1 antibody (IgG, 1.25 gm/ml) was generously
provided by Dr. Leslie Gold (New York University Medical
Center, New York, New York). Monoclonal antibody
T2G1 was used for staining of fibrin. Monoclonal antibody
T2G1 (6.7 g/ml, Centocor, Malvern, Pennsylvania) reacts
with B 15 to 42 peptides as well as fibrin II and
cross-linked fibrin II.
Immunocytochemical staining. Immunocytochemistry
was done on serial sections from each tissue specimen. After
deparaffinization, endogenous peroxidase activity was
blocked with 0.3% H2O2 in methanol. Nonspecific binding
of the polyclonal antibodies was blocked by incubation with
10% normal goat serum or 10% normal horse serum in
phosphate buffered saline (PBS), 1% body surface area
depending on the source of secondary antibody. Slides were
incubated with primary antibody for 1 h at room tempera-
ture. After washing with PBS, slides were incubated with
secondary antibody for 1 h at room temperature. Two kinds
of secondary antibodies were used. A biotinylated horse
anti-mouse IgG (Vector Laboratories, Inc., Burlingame,
California) was used with mouse primary antibody, whereas
a biotinylated goat anti-rabbit IgG (Vector Laboratories,
Inc.) was used with rabbit primary antibody. Further stain-
ing was performed using the avidin-biotin-peroxidase tech-
nique (Vectastain, Vector Laboratories, Inc.). DAB (3,3-
Diaminobenzidine Tetrahydrochloide, Sigma, St. Louis,
Missouri) was used as a chromogen. Tissues were then
counterstained with either methylgreen or hematoxylin. To
confirm activity of the antisera, tissues positive for the various
antisera such as human tonsil (anti-human -smooth muscle
actin, CD 68, and MIB-1), human bladder (HABP), monkey
pulmonary artery (TGF-1), and human organizing thrombi
(-fibrin) were used. Negative control sections were incubated
with same concentration of either normal mouse serum or
normal rabbit serum depending upon the source of primary
antibody instead of primary antiserum.
Antigen retrieval technique (14) was used for 4%
paraformaldehyde-fixed tissue. Briefly, after deparaffiniza-
tion, hydration, and blocking of endogenous peroxidase
with 0.3% H2O2, slides were placed in a plastic container
that was filled with 10 mM sodium citrate, pH 6.0. Slides
were heated in a microwave oven (800 W) for 8 min. After
heating, the container was removed from the oven and
allowed to cool for 20 min at room temperature. After slides
were rinsed in PBS, further immunohistochemical staining
was performed on the slides.
Hyaluronan labeling was done with biotinylated HABP.
After deparaffinization, tissue specimens were dehydrated
with graded ethanol. Endogenous peroxidase activity was
blocked with 0.3% H2O2 in 100% methanol. For negative
control, human bladder tissue was digested with hyaluron-
idase (20 U/ml, 0.2 M sodium acetate, pH 5.5) for 1 h at
37°C. Nonspecific binding was blocked by incubation with
10% normal goat serum in PBS, 1% BSA for 1 h. Slides
were incubated with biotinylated HABP (2 to 4 g/ml) in
Figure 1. Bar graph showing the distribution of age of specimens after
stent deployment. DCA  directional coronary angioplasty.
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5% normal goat serum/PBS overnight at 4°C. Slides were
rinsed three times in PBS, and further staining was per-
formed using the avidin-biotin peroxidase technique.
Transmission electron microscopy. After initial fixation
and transport in 4% paraformaldehyde/PBS, the tissue was
rinsed for 5 min with 0.1 M cacodylate, pH 7.3, and treated
for 2 h with a fixative that includes 2.5% glutaraldehyde and
2.0% paraformaldehyde in 0.1 M cacodylate and 0.2%
ruthenium red (Johnson-Matthey Co., West Hill, Massa-
chusetts) to stabilize the proteoglycan component of the
ECM, as described (15). After multiple rinses with 0.1 M
cacodylate containing 0.1% ruthenium red, the tissue was
postfixed with 1% osmium tetroxide and 0.05% ruthenium
red in 0.1 M cacodylate for 2 h. After rinsing with water, the
tissue was processed routinely for plastic embedment with
dehydration through graded ethanol and infiltration with
the epoxy resin Medcast (Pelco, Redding, California).
Ultrathin sections (80 to 100 nm) were stained with 6%
aqueous uranyl acetate and lead citrate.
Statistics. All statistics were calculated by use of SPSS 7.5
for Windows, and data are expressed as mean  SD. To
compare the frequency of specimens containing either
cell-depleted areas or myxoid tissue between different stent
age groups, we used Fisher exact test. A value of p  0.05
indicates statistical significance.
RESULTS
To facilitate any recognition of changes over time, these
specimens were grouped into three categories: stented for
under 3 months (n 9), between 3 and 6 months (n 13),
and more than 6 until 23 months (n  7).
Cellularity of lesion. The cellularity of stent neointima, in
general, decreases in time after stenting. The early lesion is
Figure 2. Hematoxylin- and eosin-stained tissues retrieved from human coronary stent neointima of three different stent age groups. (A-1) Stent neointima
at two months after stenting shows hypercellular myxoid tissue characterized by stellate-shaped smooth muscle cells arranged in a disorganized pattern
(high-power field, A-2). Smooth muscle cells were identified by immunostaining for -actin staining of adjacent section (A-3). (B-1) Stent neointima at
three months after stenting shows both cell-depleted areas with dense extracellular matrix (ECM) (thick arrow) and a lesion of moderate cellularity with
loose ECM (thin arrow). High-power field (B-2) and immunostaining for -actin staining (B-3). (C) Stent neointima at 11 months after stenting shows
two kinds of cell-depleted areas: one with dense ECM (thick arrow) and the other with loose ECM (thin arrow). Bar  100 m.
Figure 3. Bar graph showing the frequency of specimens containing foci of cell-depleted areas. Note that specimens with foci of cell depleted areas tend
to increase over time after stenting. *p  0.01 for both 3 to 6 months and 6 months vs. 3 months. DCA  directional coronary angioplasty.
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hypercellular, whereas the late lesion becomes hypocellular
(Fig. 2). The majority (59%) of lesions contain cell-depleted
areas (Table 1). Interestingly, the frequency of specimens
containing cell-depleted areas increases over time after stent
deployment (Fig. 3) (1 of 9 in 3 months vs. 10 of 13 in 3
to 6 months after stenting, p  0.01; 1 of 9 in 3 months
vs. 6 of 7 in 6 months after stenting, p  0.01). At other
sites in the stent neointima, myxoid tissue characterized by
stellate-shaped cells in a disorganized pattern was observed
(Fig. 2). As can be seen in Figure 4, the frequency of
specimens containing myxoid tissue diminishes in time after
stenting (8 of 9 in 3 months vs. 2 of 7 in 6 months, p
 0.05). The majority of cells in these specimens were
labeled with -smooth muscle actin, confirming that they
are SMC (Fig. 2). Specimens were also stained with
antibodies (CD68), which recognize macrophages. Nine of
15 samples showed no CD68-positive cells, while the
remaining samples contained 1 to 12 macrophages per
section (data not shown). Thus, stent neointima is primarily
composed of SMC with minimal inflammatory cells.
Cell proliferation. Overall, very few replicating cells
(range, 0% to 4%) as assessed by Ki-67 staining were noted,
and 16 of 26 analyzed specimens exhibited no replicating
cells (Table 1). Ten specimens had more than one Ki-67-
positive cell, and two specimens had more than 1% Ki-67-
positive cells. The maximum number of Ki-67-positive cells
were observed in a specimen that was taken 23 months after
stent deployment (Fig. 5). When these data were organized
into three groups with respect to time after stenting, the
same pattern was observed (Fig. 6). Low cell replication rate
of all specimens was also confirmed by PCNA immunola-
beling (data not shown).
Identification of ECM. The majority of specimens after
three months after stenting demonstrated cell-depleted
areas. Two kinds of cell-depleted areas were noted:
collagen-rich or collagen-poor as determined by histochem-
ical staining. There was little staining for proteoglycans in
the collagen-rich, cell-depleted areas. Immunocytochemis-
try revealed that the proteoglycan biglycan was commonly
associated with collagen-rich areas in approximately 60% of
cases. The collagen-poor, cell-depleted areas immuno-
stained for a variety of proteoglycans in which versican was
most prominent (Fig. 7). Hyaluronan, and to a lesser degree
perlecan, was also noted at these collagen-poor sites. There
was a general tendency for collagen to accumulate in the
ECM over time after stenting, whereas proteoglycans were
more frequently observed in the early period after stenting
(Table 1). In myxoid tissue, proteoglycans were dispersed
diffusely (Fig. 8), and versican was, in general, dominant
although hyaluronan and biglycan were also identified in
these zones. Perlecan staining was minimal and was usually
Figure 4. Bar graph showing the frequency of specimens containing myxoid tissue. Note that specimens with myxoid tissue tend to decrease over time after
stenting. *p  0.05 for 6 months vs. 3 months. DCA  directional coronary angioplasty.
Figure 5. Immunostaining for Ki-67 shows one positive nucleus (brown color, arrow) in the myxoid tissue of human coronary stent neointima at 2.5
months after stenting (A). In tissue of stent neointima at 23 months after stenting, several Ki-67-positive nuclei were noted (B). Tissue of human tonsil
as a positive control shows many positive Ki-67-stained nuclei of lymphocytes in the follicular structure (C). Counterstaining with either hematocylin (A,
B) or methylgreen (C). Bar  100 m.
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localized in the matrix surrounding SMC (Fig. 8). Most of
myxoid tissue examined by electron microscopy exhibited
ECM enriched in ruthenium red positive granules depicting
proteoglycans with occasional immature segments of elastic
fibers present (Fig. 9).
These samples were also examined for the presence of
fibrin. Fibrin was present in only 6 of 21 specimens (Table
1). In five specimens the fibrin staining was mostly found in
cell-depleted areas (Fig. 7). There was no correlation
between the presence of fibrin and time after stenting.
The ECM-enriched regions contained TGF-1-positive
cells throughout the stent neointima (Fig. 4). Sixteen of 20
specimens stained positive with anti-TGF-1 antibody.
Transforming growth factor-1 immunostaining tended to
be abundant in myxoid tissue.
DISCUSSION
Conventional wisdom is that the critical lesion of in-stent
neointima is an excess of proliferative SMCs. Our data
indicate that proliferation is not a factor contributing to
in-stent restenosis at times greater than two months after
interventions. Instead, the in-stent neointima in human
specimens consists primarily of large amounts of a
proteoglycan-rich ECM with a relatively small number of
proliferative SMCs. A major finding in this study is the
variability of cellularity in stent neointima. Cell-depleted
Figure 6. Numbers of in-stent restenotic specimens grouped according to various degrees of Ki-67 nuclear antigen labeling. Note that, regardless of stent
age, majority of specimens had no Ki-67 labeling. Solid bar  3 months; hatched bar  3 to 6 months; diamond bar  6 months.
Figure 7. Immunohistochemical analysis of extracellular matrix (ECM) of cell-depleted areas in human coronary stent neointimal tissue sections adjacent
to the section of Figure 2C. In modified Movat staining, two kinds of cell-depleted areas were characterized. The collagen-rich ECM (pinkish yellow, thick
arrow) is colocalized with the dense matrix seen in Figure 2C, and the proteoglycan-rich ECM (blue, thin arrow) with the loose matrix. Fibrin and/or
fibrinogen are labeled as red (asterisk). Versican is abundant in the proteoglycan-rich area (brown, thin arrow), but is spared in the collagen-rich ECM
(thick arrow). The distribution of hyaluronan is similar to that of versican. The biglycan-stained area is mostly colocalized with the dense collagen-rich
matrix (brown, thick arrow). A few fibrin-labeled areas (dark brown) assessed by T2G1 antibodies are shown, counterstaining with methylgreen. Bar 
100 m.
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Figure 8. Immunohistochemical analysis of myxoid tissue in atherectomized human coronary stent neointima at two months after stenting. In modified
Movat’s staining, this specimen is composed of two different kinds of tissue: one is the myxoid tissue (labeled as M) enriched in blue-colored proteoglycans,
and the other is collagen-rich cell-depleted area (labeled as C). Both versican and hyaluronan are abundant in this myxoid tissue, whereas both molecules
are spared in the collagen-rich cell-depleted area. Perlecan staining shows labeling around the stellate-shaped smooth muscle cells. Transforming growth
factor-1 staining shows cytoplasmic labeling in the stellate cells. Counterstaining with either methylgreen or hematoxylin. Bar  100 m.
Figure 9. Transmission electron micrograph of an atherectomized human coronary stent neointima specimen containing the loose proteoglycan-rich matrix.
Extracellular matrix contained numerous ruthenuium red positive proteoglycan granules, often linked together by fine filamentous threads, and occasional
segments of immature elastin (labeled as E). Bar  500 nm.
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areas are identified in 59% of cases and tended to increase
with time after stent deployment. The cell density observed
in cell-depleted areas (mean: 194; range: 48 to 320 cells/
mm2) is as low as that detected in primary atherosclerosis
(10). Other data (5) show a trend toward reduction in the
cell density of the coronary arterial neointima formed after
stenting with time. These data are consistent with the cell
replication data in our study. Both Ki-67 nuclear antigen
and PCNA labeling indexes are low, in most cases below
1%. This is true regardless of the period of time after
stenting. Furthermore, the myxoid tissue observed in this
study did not exhibit enhanced proliferative activity as
others have observed (6,8). Thus, in-stent neointima may be
a stable end-stage tissue similar to the advanced atheroscle-
rotic plaque where both cell replication and death reach a
minimal level. The low replication rate is also observed in
primary lesions and in restenotic lesions after either stent
implantation or balloon angioplasty (5,9,16). Furthermore,
there are several studies in experimental animals to indicate
that reinjury to existing intimal lesions stimulates low and
transitory proliferative response by SMC (17,18). Smooth
muscle cells cultured from human lesions also exhibit a
marked decrease in the ability to replicate (19). Differences
in detecting replication rates may reflect use of different
reagents to detect proliferation. Ki-67 detects replicative
cells more accurately than PCNA (20,21). However, it is
possible that overestimates of cell proliferation can be made
because both Ki-67 and PCNA are positive in proliferating
cells not only during S phase, but also during the G1 and
G2 phase of the cell cycle (16,20). One shortcoming of our
study is that we are unable to rule out the possibility of
transient increases in cell replication during the period
immediately after stent insertion due to lack of specimens at
this time period.
There are at least two possible mechanisms to explain the
occurrence of cell-depleted areas in the stent restenotic
specimens. One is cell death, and the other is ECM
expansion in the absence of cell proliferation. As it may well
be that both are operative, the recent observation that
reduction in vascular tensile stress induced programmed cell
death suggests that cell death may play a role (22). For
example, the expansion of the stent in the artery should lead
to a decrease in tension in the neointima formed inside of
stent. Therefore, cell loss might be an expected outcome.
On the other hand, it is quite clear that the bulk of the
lesion mass after stenting is due to accumulation of specific
components of the ECM. Cell-depleted areas are charac-
terized by both collagen-rich as well as proteoglycan-rich
ECMs. Similar reciprocal ECM patterns of collagen and
proteoglycan are observed in human restenotic peripheral
arteries (23). However, in the present study, collagen-rich
ECMs tended to be more common in cell-depleted areas
suggesting that this ECM component may play a role in cell
death (24,25).
The accumulation of ECM in these specimens may be
influenced by the presence of TGF-1. Extracellular matrix
accumulation in lesions of atherosclerosis and restenosis
occurs in TGF-1-positive areas (26,27). Transforming
growth factor-1 may be derived from resident vascular cells
(28) or from platelet degranulation (29). Transforming
growth factor-1 is elevated in vascular SMC of human
coronary and peripheral arteries, and was significantly
higher in restenotic lesions compared with primary lesions
(27). Transforming growth factor-1 is known to regulate
the synthesis and turnover of a variety of ECM components
such as proteoglycans, hyaluronan, fibronectin, and collagen
(30–34). Interestingly, blocking TGF-1 activity after vas-
cular injury dramatically decreases ECM accumulation and
suppressed intimal hyperplasia in the rat model of arterial
injury (35).
Hyaluronan is abundant, especially in myxoid tissue, and
is scarce in collagen-rich cell-depleted areas in our speci-
mens. Similar inverse relation between hyaluronan and
collagen was previously observed in human restenotic pe-
ripheral arteries (36). Hyaluronan accumulation around
PCNA-positive SMCs is observed in human restenotic
arteries and in injured rat carotid arteries, suggesting that
hyaluronan significantly contributes to expansion of the
neointima (36,37), possibly through the trapping of water
and tissue swelling. In experimental animal studies, an
increase of ECM hyaluronan is found to be responsible for
the closing ductus arteriosus during fetal development (38).
Hyaluronan may also influence in-stent restenosis by pro-
moting the migration of SMCs (39–41).
On the other hand, hyaluronan may effect the constrictive
remodeling that occurs in this form of restenosis. For
example, hyaluronan added to collagen gels promotes col-
lagen gel contraction by SMC (42), suggesting that hyal-
uronan could also promote vessel shrinkage if bound to
collagen. However, in most cases hyaluronan was not
present in collagen-rich regions in the stent restenotic
samples.
Surprisingly, we observed little fibrin labeling (29% of
cases) in these samples, which is lower than observed by
others (6). Low frequency of fibrin deposits suggests that
acute thrombosis does not play a significant role in the
restenosis of stented arteries as shown in a recent clinical
study in which acute thrombosis occurred in only 1.4% of
cases (43).
Our study shows that ECM accumulation, rather than
cell proliferation, in the developing in-stent lesion at two
months or greater contributes to lesion severity. This
concept is supported by the recent study showing that high
activity 32P radioactive stent promotes the formation of
neointima after six months in porcine coronary stent models
(44). We cannot rule out the involvement of cell prolifera-
tion as a contributing factor in the early time points after
stenting, nor can we rule out an involvement of cell
proliferation outside the stent such as in the adventitia
media and deep plaque. Cell proliferation is accompanied by
changes in the ECM, and such changes may, in part,
regulate the proliferative and survival properties of the cells.
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The hygroscopic property of the ECM in in-stent restenotic
tissue may limit the effectiveness of balloon angioplasty due
to transient tissue compression. This idea is supported by a
recent clinical study showing that balloon angioplasty for
treating stent restenosis led to less acute gain than at time of
stenting and carried a particularly high recurrent restenosis
rate (45). Our human aortic clonality study suggests that
intima probably originates from underlying media (46).
Therefore, on the basis of our study results, SMCs com-
prising the stent neointima may originate mostly from the
underlying atherosclerotic plaque outside of stent or media,
and subsequent ECM accumulation seems to play a key role
in stent restenosis. Further study to identify the role of
myoxoid tissue may be crucial to understand the mecha-
nisms.
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